Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas

被引：8

作者：

Sonnenblick, Amir ^{[1
]}

Eleyan, Feras ^{[1
]}

Peretz, Tamar ^{[1
]}

Ospovat, Inna ^{[2
]}

Merimsky, Ofer ^{[2
]}

Sella, Tamar ^{[3
]}

Peylan-Ramu, Nili ^{[1
]}

Katz, Daniela ^{[1
]}

机构：

[1] Hadassah Hebrew Univ, Med Ctr, Sharett Inst Oncol, POB 12000, IL-91120 Jerusalem, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Oncol, IL-69978 Ramat Aviv, Israel

[3] Hadassah Hebrew Univ, Med Ctr, Dept Radiol, IL-91120 Jerusalem, Israel

来源：

MOLECULAR AND CLINICAL ONCOLOGY | 2015年 / 3卷 / 04期

关键词：

gemcitabine; paclitaxel; soft-tissue sarcomas; stage; 4;

D O I：

10.3892/mco.2015.545

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A limited number of chemotherapeutic agents have been found to be active against advanced soft-tissue sarcomas (STSs), particularly sarcomas that have progressed following doxorubicin treatment. The aim of this retrospective study was to determine the response to treatment with gemcitabine plus paclitaxel in patients with STSs. Data were collected on all patients with advanced non-resectable STS who were treated with a fixed dose 700 mg/m(2) gemcitabine in combination with 70 mg/m(2) paclitaxel on days 1 and 8 every 3 weeks. A total of 30 patients were included, with a median age of 56.4 years (range, 40-70 years). The gemcitabine/paclitaxel combination was well tolerated, with an overall response in 27% and a clinical benefit in 57% of the patients. The median progression-free survival was 6.1 months and the overall survival was 14.3 months. In conclusion, gemcitabine plus paclitaxel was found to be tolerable and effective in patients with advanced STSs.

引用

页码：829 / 832

页数：4

共 20 条

[1] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[2] Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine lelomyosarcoma: A Gynecologic Oncology Group phase II trial [J].

Hensley, Martee L. ;

Blessing, John A. ;

Mannel, Robert ;

Rose, Peter G. .

GYNECOLOGIC ONCOLOGY, 2008, 109 (03) :329-334

[3] Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas [J].

Hensley, Martee L. .

CURRENT OPINION IN ONCOLOGY, 2010, 22 (04) :356-361

[4] Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial [J].

Hensley, ML ;

Maki, R ;

Venkatraman, E ;

Geller, G ;

Lovegren, M ;

Aghajanian, C ;

Sabbatini, P ;

Tong, W ;

Barakat, R ;

Spriggs, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2824-2831

[5]

Kellokumpu-Lehtinen P, 2013, ANTICANCER RES, V33, P2623

[6] Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma [J].

Leu, KM ;

Ostruszka, LJ ;

Shewach, D ;

Zalupski, M ;

Sondak, V ;

Biermann, JS ;

Lee, JSJ ;

Couwlier, C ;

Palazzolo, K ;

Baker, LH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1706-1712

[7] Phase III trial of two Investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study [J].

Lorigan, Paul ;

Verweij, Jaap ;

Papai, Zsuzsa ;

Rodenhuis, Sjoerd ;

Le Cesne, Axel ;

Leahy, Michael G. ;

Radford, John A. ;

Van Glabbeke, Martine M. ;

Kirkpatrick, Anne ;

Hogendoorn, Pancras C. W. ;

Blay, Jean-Yves .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) :3144-3150

[8] Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas [J].

Maki, Robert G. ;

Wathen, J. Kyle ;

Patel, Shreyaskumar R. ;

Priebat, Dennis A. ;

Okuno, Scott H. ;

Samuels, Brian ;

Fanucchi, Michael ;

Harmon, David C. ;

Schuetze, Scott M. ;

Reinke, Denise ;

Thall, Peter F. ;

Benjamin, Robert S. ;

Baker, Laurence H. ;

Hensley, Martee L. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2755-2763

[9] Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study [J].

Merimsky, O ;

Meller, I ;

Flusser, G ;

Kollender, Y ;

Issakov, J ;

Weil-Ben-Arush, M ;

Fenig, E ;

Neuman, G ;

Sapir, D ;

Ariad, S ;

Inbar, M .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (02) :177-181

[10] Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma [J].

Navid, Fariba ;

Willert, Jennifer Reikes ;

McCarville, M. Beth ;

Furman, Wayne ;

Watkins, Amy ;

Roberts, William ;

Daw, Najat C. .

CANCER, 2008, 113 (02) :419-425

← 1 2 →